BenefitsAdverse Effects
  • In patients with inadequate disease control who required a change in treatment, combination therapy with a biologic DMARD and MTX achieved greater improvements in some outcomes than either a biologic DMARD or MTX alone.
    • Combination therapy achieves greater improvement than biologic DMARDs alone in:
      • Disease activity and radiographic progression Image clinra2fu2.jpg
    • Combination therapy achieves greater improvement than MTX alone in:
      • Clinical response and functional capacity Image clinra2fu1.jpg
      • Quality of life Image clinra2fu2.jpg
  • In patients whose RA failed to respond to first-line MTX, combination therapy with MTX and a biologic DMARD was not more successful than monotherapy with a biologic DMARD. Image clinra2fu2.jpg
  • In MTX-na├»ve patients or those not recently on MTX, combination therapy is superior to monotherapy with a biologic DMARD for functional capacity Image clinra2fu2.jpg and quality of life Image clinra2fu3.jpg.
  • Combining MTX or other oral DMARDs with a biologic DMARD does not alter the adverse event rate found with the biologic DMARD alone. Image clinra2fu3.jpg
  • Combining MTX and biologic DMARDs demonstrates a better tolerability profile than MTX alone. Image clinra2fu3.jpg
  • The evidence is insufficient to estimate differences in rates of specific adverse events between the biologic and oral DMARDS. Image clinra2fu4.jpg

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.